Virpax Announces Positive Results of Swine Model Pilot Study for Probudur™
Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding
Virpax® Pharmaceuticals to Present at 2024 BIO International Convention
Virpax Announces Pricing of $2.25 Million Public Offering
Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™
Virpax Pharmaceuticals Reports 2023 Year-End Results
Scilex Entered into a Agreement with Virpax Pharmaceuticals
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price